{"DataElement":{"publicId":"5097997","version":"1","preferredName":"Protocol Treatment Arm Maximum Tolerated Dose Schedule Assignment Category","preferredDefinition":"Text term that represents the choice of Arm maximum tolerated dose schedule.","longName":"ARM_MTD_DOSE_SCH_CAT","context":"ABTC","contextVersion":"1","DataElementConcept":{"publicId":"5097993","version":"1","preferredName":"Protocol Treatment Arm Maximum Tolerated Dose Schedule Assignment","preferredDefinition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study._The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found._An ordered list of times at which things are planned to occur._An allotting or an appointment to a particular person or use, or for a particular time or object.","longName":"2454523v1.0:5097991v1.0","context":"ABTC","contextVersion":"1","ObjectClass":{"publicId":"2454523","version":"1","preferredName":"Protocol Treatment Arm","preferredDefinition":"A specific treatment protocol used in a clinical trial.","longName":"C15538","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E070B71-91E4-1732-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-10","modifiedBy":"ONEDATA","dateModified":"2006-03-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5097991","version":"1","preferredName":"Maximum Tolerated Dose Schedule Assignment","preferredDefinition":"The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.:An ordered list of times at which things are planned to occur.:An allotting or an appointment to a particular person or use, or for a particular time or object.","longName":"C94489:C25211:C25426","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maximum Tolerated Dose","conceptCode":"C94489","definition":"The highest dose of a drug or treatment that does not cause unacceptable side effects. The maximum tolerated dose is determined in clinical trials by testing increasing doses on different groups of people until the highest dose with acceptable side effects is found.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Schedule","conceptCode":"C25211","definition":"An ordered list of times at which things are planned to occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C72847-82F2-0FDD-E050-BB89AD4310D1","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-07","modifiedBy":"ONEDATA","dateModified":"2016-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C72847-8303-0FDD-E050-BB89AD4310D1","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for ABTC-1202 study in Rave per request by J.Zhao. mc 1/7/2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5097994","version":"1","preferredName":"ABTC Dose Schedule Category","preferredDefinition":"A grouping of items based on some commonality or by user defined characteristics.","longName":"DOSE_SCH_CAT","context":"ABTC","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Arm 1 MTD (200 mg Days 1-5)","valueDescription":"Arm 1 MTD (200 mg Days 1-5)","ValueMeaning":{"publicId":"5097996","version":"1","preferredName":"Arm 1 MTD (200 mg Days 1-5)","longName":"5097996","preferredDefinition":"Arm 1 MTD (200 mg Days 1-5)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C72847-8354-0FDD-E050-BB89AD4310D1","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"28C72847-836D-0FDD-E050-BB89AD4310D1","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-07","modifiedBy":"ONEDATA","dateModified":"2016-01-07","deletedIndicator":"No"},{"value":"Arm 2 MTD (425 mg Days 1-5)","valueDescription":"Arm 2 MTD (425 mg Days 1-5)","ValueMeaning":{"publicId":"5097995","version":"1","preferredName":"Arm 2 MTD (425 mg Days 1-5)","longName":"5097995","preferredDefinition":"Arm 2 MTD (425 mg Days 1-5)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C72847-8331-0FDD-E050-BB89AD4310D1","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2928BF91-878E-0C29-E050-BB89AD430A30","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-12","modifiedBy":"ONEDATA","dateModified":"2016-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C72847-831C-0FDD-E050-BB89AD4310D1","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-07","modifiedBy":"COOPERM","dateModified":"2016-01-12","changeDescription":"Created for ABTC-1202 study in Rave per request by J.Zhao. mc 1/7/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4280691","version":"1","longName":"CRF CDEs","context":"ABTC","ClassificationSchemeItems":[{"publicId":"4280719","version":"1","longName":"Dosing","context":"ABTC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Dose Schedule Choice","type":"Preferred Question Text","description":"Dose Schedule Choice","url":null,"context":"ABTC"}],"origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C7B1DC-1CD7-7913-E050-BB89AD430E52","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-07","modifiedBy":"COOPERM","dateModified":"2016-01-12","changeDescription":"Created for ABTC-1202 study in Rave per request by J.Zhao. mc 1/7/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}